# Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

> **NCT05057221** · PHASE1,PHASE2 · TERMINATED · sponsor: **Lena Napolitano, MD** · enrollment: 6 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Uproleselan

## Key facts

- **NCT ID:** NCT05057221
- **Lead sponsor:** Lena Napolitano, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-12
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** No more eligible patients were available.
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057221, "Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05057221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*